KR20080030546A - 레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법 - Google Patents

레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법 Download PDF

Info

Publication number
KR20080030546A
KR20080030546A KR1020077007855A KR20077007855A KR20080030546A KR 20080030546 A KR20080030546 A KR 20080030546A KR 1020077007855 A KR1020077007855 A KR 1020077007855A KR 20077007855 A KR20077007855 A KR 20077007855A KR 20080030546 A KR20080030546 A KR 20080030546A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
weight
total weight
composition according
levetiracetam
Prior art date
Application number
KR1020077007855A
Other languages
English (en)
Korean (ko)
Inventor
마이클 데렐스
쟝-베노잇 허벌트
Original Assignee
유씨비 파마, 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20080030546(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유씨비 파마, 에스.에이. filed Critical 유씨비 파마, 에스.에이.
Publication of KR20080030546A publication Critical patent/KR20080030546A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077007855A 2005-07-26 2006-07-24 레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법 KR20080030546A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05016189 2005-07-26
EP05016189.2 2005-07-26
EP05016945.7 2005-08-04
EP05016945 2005-08-04

Publications (1)

Publication Number Publication Date
KR20080030546A true KR20080030546A (ko) 2008-04-04

Family

ID=36888840

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077007855A KR20080030546A (ko) 2005-07-26 2006-07-24 레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법

Country Status (26)

Country Link
US (1) US8802142B2 (zh)
EP (1) EP1909764B1 (zh)
JP (2) JP5183470B2 (zh)
KR (1) KR20080030546A (zh)
CN (1) CN101068534B (zh)
AR (1) AR054581A1 (zh)
AU (1) AU2006274263B2 (zh)
BR (1) BRPI0606121A2 (zh)
CA (1) CA2581831C (zh)
CY (1) CY1115825T1 (zh)
DK (1) DK1909764T3 (zh)
EA (1) EA014961B1 (zh)
ES (1) ES2524771T3 (zh)
HK (1) HK1109071A1 (zh)
HR (1) HRP20141185T1 (zh)
IL (1) IL182375A0 (zh)
MX (1) MX2007004294A (zh)
NO (1) NO20071667L (zh)
NZ (1) NZ554157A (zh)
PE (2) PE20070216A1 (zh)
PL (1) PL1909764T3 (zh)
PT (1) PT1909764E (zh)
RS (1) RS53690B1 (zh)
SI (1) SI1909764T1 (zh)
TW (1) TW200738280A (zh)
WO (1) WO2007012439A1 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE05815688T1 (de) 2005-01-27 2008-06-26 Alembic Ltd. Levetiracetam-formulierung mit verlängerter freisetzung
CA2637925A1 (en) * 2006-01-24 2007-08-02 Teva Pharmaceutical Industries Ltd. Levetiracetam formulations and methods for their manufacture
FR2912056B1 (fr) * 2007-02-05 2009-12-18 Rd Pharmagal Composition a liberation prolongee de levetiracetam et procede de preparation
JP2010024156A (ja) * 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN101422442A (zh) * 2008-12-09 2009-05-06 沈阳药科大学 左乙拉西坦渗透泵控释片及其制备方法
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
ES2511047T3 (es) * 2009-01-29 2014-10-22 Ucb Pharma, S.A. Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina
DK2445570T3 (da) 2009-06-26 2013-02-25 Taris Biomedical Inc Implanterbare lægemiddelafgivelsesindretninger samt fremgangsmåder til deres fremstilling
CN102038657B (zh) * 2009-10-10 2015-04-15 浙江华海药业股份有限公司 左乙拉西坦片及其制备方法
CA2789307A1 (en) * 2010-03-29 2011-10-06 Hetero Research Foundation Stable pharmaceutical composition of imatinib
TR201011148A1 (tr) 2010-12-30 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Levetirasetam farmasötik bileşimleri.
EP3400934A1 (en) * 2011-02-09 2018-11-14 The Johns Hopkins University Levetiracetam for improving cognitive function
CN102188420B (zh) * 2011-03-25 2013-04-10 华润赛科药业有限责任公司 一种左乙拉西坦的药物组合物及其制备方法
CN102871981B (zh) * 2012-10-25 2013-11-13 杭州朱养心药业有限公司 包含左乙拉西坦的片剂药物组合物
CN102895214B (zh) * 2012-10-25 2014-03-26 杭州朱养心药业有限公司 左乙拉西坦片剂的固体药物组合物
CN103127175B (zh) * 2013-02-22 2014-01-22 张晓光 一种抗癫痫药物及其制备方法
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
MX365513B (es) 2013-03-15 2019-06-06 Aprecia Pharmaceuticals LLC Forma de dosificacion de dispersion rapida que contiene levetiracetam.
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
US20170035733A1 (en) * 2013-11-29 2017-02-09 Ucb Pharma Gmbh Pharmaceutical composition comprising lacosamide and levetiracetam
CN104666263B (zh) * 2015-02-09 2017-07-11 海南华益泰康药业有限公司 一种含有左乙拉西坦的片剂及其制备方法
CA2986598C (en) * 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP6630229B2 (ja) * 2016-05-17 2020-01-15 エルメッド株式会社 レベチラセタム含有医薬組成物及びその製造方法
JP6422464B2 (ja) * 2016-05-19 2018-11-14 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
CN107913258A (zh) * 2016-10-09 2018-04-17 北京阜康仁生物制药科技有限公司 一种左乙拉西坦缓释片及其制备方法
JP6326114B2 (ja) * 2016-11-01 2018-05-16 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤
JP7264711B2 (ja) * 2019-04-26 2023-04-25 東和薬品株式会社 レベチラセタム含有医薬組成物の製造方法
JP7575217B2 (ja) 2019-08-09 2024-10-29 日本ジェネリック株式会社 レベチラセタムを含む錠剤
CN117838643A (zh) * 2023-12-29 2024-04-09 山东力诺制药有限公司 一种吡拉西坦片及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
EP0618983B1 (en) * 1992-10-09 1999-09-01 VYSIS, Inc. Insertion elements and amplifiable nucleic acids
BE1011045A3 (fr) 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
IL149530A0 (en) 1999-12-01 2002-11-10 Ucb Sa A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
DE60204224T2 (de) * 2001-03-22 2006-02-02 Ucb S.A. Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
WO2003094913A1 (en) * 2002-05-14 2003-11-20 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
JP2006516390A (ja) 2002-12-03 2006-07-06 ユ セ ベ ソシエテ アノニム 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
CN1802352A (zh) * 2003-02-03 2006-07-12 特瓦制药工业有限公司 制备左乙拉西坦的方法
CA2526562C (en) * 2003-05-23 2011-06-28 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
DE05815688T1 (de) 2005-01-27 2008-06-26 Alembic Ltd. Levetiracetam-formulierung mit verlängerter freisetzung

Also Published As

Publication number Publication date
RS53690B1 (en) 2015-04-30
SI1909764T1 (sl) 2015-01-30
MX2007004294A (es) 2008-03-11
EP1909764A1 (en) 2008-04-16
IL182375A0 (en) 2007-07-24
NZ554157A (en) 2010-12-24
TW200738280A (en) 2007-10-16
CA2581831C (en) 2013-11-12
BRPI0606121A2 (pt) 2009-10-06
US8802142B2 (en) 2014-08-12
AU2006274263A1 (en) 2007-02-01
CN101068534A (zh) 2007-11-07
AR054581A1 (es) 2007-06-27
JP2009502835A (ja) 2009-01-29
EP1909764B1 (en) 2014-09-10
PT1909764E (pt) 2014-12-18
JP2013018786A (ja) 2013-01-31
HRP20141185T1 (hr) 2015-01-30
PE20100265A1 (es) 2010-04-21
JP5183470B2 (ja) 2013-04-17
ES2524771T3 (es) 2014-12-12
PL1909764T3 (pl) 2015-03-31
NO20071667L (no) 2007-04-26
CN101068534B (zh) 2011-09-07
DK1909764T3 (da) 2014-12-15
CY1115825T1 (el) 2017-01-25
US20080269316A1 (en) 2008-10-30
PE20070216A1 (es) 2007-03-27
CA2581831A1 (en) 2007-02-01
AU2006274263B2 (en) 2011-01-27
HK1109071A1 (en) 2008-05-30
EA200700566A1 (ru) 2008-08-29
WO2007012439A1 (en) 2007-02-01
EA014961B1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
KR20080030546A (ko) 레베티라세탐을 포함하는 약제 조성물 및 이의 제조 방법
EP2285357B1 (en) Pharmaceutical compositions comprising brivaracetam
JP5576401B2 (ja) ２−オキソ−１−ピロリジン誘導体を含む医薬組成物
US20080014271A1 (en) Novel pharmaceutical compositions comprising levetiracetam
EP2391351B1 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
EP2490675B1 (en) Pharmaceutical compositions of sevelamer
KR20090016611A (ko) 메만틴의 약학 조성물
WO2008144730A2 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
CA2696977A1 (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
EP2804588B1 (en) Method for producing cinacalcet compositions for direct tableting
KR20120128599A (ko) 아트로바스타틴 함유 피복 제제
US20230022228A1 (en) Pharmaceutical composition comprising eltrombopag bis(monoethanolamine)
CN108379233B (zh) 一种甲基多巴组合物、片剂及制备方法
US20070087055A1 (en) Directly compressible extended release alprazolam formulation
KR20210105381A (ko) 리팍시민 정제의 제조 방법 및 리팍시민 정제
EP2295037A1 (en) Pharmaceutical formulation containing Ribavirin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application